Evaluation of Respiratory Function During Self-induced Cognitive Trance
- Conditions
- Respiratory Function
- Interventions
- Diagnostic Test: spirometry
- Registration Number
- NCT06121960
- Lead Sponsor
- Centre Hospitalier Metropole Savoie
- Brief Summary
The goal of this Prospective, monocentric, non-randomized, open-label study aimed at evaluating the variation of FEV1 during a state of self-induced cognitive trance participant population: Person with expertise in the practice of TCAI can be inclued. (at least 6 months, in order to be able to control the depth of the trance and to have a motor control allowing the realization of a spirometry)
The main question:
Study the significant variation of FEV1 before, during, or after the state of self-induced cognitive trance
- Detailed Description
Primary objective : Study the significant variation of FEV1 before, during, or after the state of self-induced cognitive trance judgment criteria:
Significant variations in:
PEF PEF25 PEF50 PEF75 FVC Inspiratory capacity, SpO2 Respiratory rate before, during, or after the self-induced cognitive trance state Evolution of the feeling of self-efficacy, assessed by questionnaire
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
- Person over 18 years old
- Person with expertise in the practice of TCAI. (at least 6 months, in order to be able to control the depth of the trance and to have a motor control allowing the realization of a spirometry)
- Person affiliated with social security or beneficiary of such a scheme.
- Person having given, in writing, their free and informed consent to participate in the study
- Person deprived of liberty by judicial or administrative decision, person subject to a measure of legal protection.
- Exclusion period for other studies
- Person likely, according to the investigator's assessment, not to be cooperative or respectful of the obligations inherent in participation in the study
- Person with a psychiatric, neurological or cardiovascular disease.
- Person with a chronic respiratory disease, for example: asthma, COPD, interstitial lung disease, bronchial dilation, cystic fibrosis,
- Person with a history of exercise-induced bronchospasm.
- Person taking inhaled treatments (corticotherapy, bronchodilators, anticholinergics)
- Pregnant woman (declarative).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Interventionnal spirometry Measure DEP, DEM25, DEM 50, DEM 75, FVC, Inspiratory capacity, SpO2, Respiratory rate before, during, or after the state of self-induced cognitive trance Evolution of the feeling of self-efficacy, assessed by questionnaire.
- Primary Outcome Measures
Name Time Method FEV during a state of self-induced cognitive trance 3 month variation of forced exhaled volume in one second between pre and post phase of cognitive transe
- Secondary Outcome Measures
Name Time Method SpO2 during a state of self-induced cognitive trance 3 month variation of SpO2 between pre, per and post phase of cognitive transe
FVC during a state of self-induced cognitive trance 3 month variation of FVC between pre, per and post phase of cognitive transe
PEF during a state of self-induced cognitive trance 3 month variation of PEF between pre, per and post phase of cognitive transe
inspiratory capacity during a state of self-induced cognitive trance 3 month variation of inspiratory capacity between pre, per and post phase of cognitive transe
respiratory rate during a state of self-induced cognitive trance 3 month variation of respiratory rate between pre, per and post phase of cognitive transe
DEM25/50/75 during a state of self-induced cognitive trance 3 month variation of DEM25/50/75 between pre, per and post phase of cognitive transe
Trial Locations
- Locations (1)
Centre Hospitalier Metropole Savoie
🇫🇷Chambéry, Savoie, France